Shire Share Discussion Threads

[albo] 20/4/2018 07:28

The Allergen statement certainly has enough options in it for them to make a bid if they want to.

[philanderer] 19/4/2018 23:43

Good summary from Bloomberg...

M&A Shouldn't Be This Easy

Shire has got an auction going almost effortlessly. Just don't expect it to go far.

[scfc1] 19/4/2018 23:40

I’m amazed they actually pulled together a bid as high as £46.50...but at present it requires c$23bn of cash and if the BOD think this is “significantly undervalued” and too heavily weighted to paper, it is hard to see how they can get near the required deal figures.

With Shire’s own existing debt and their own (plus financing the cash part of the deal) they could have in excess of $50bn, I think, that’s even before any improved offer which is required. That said, who knows what tomorrow may bring after today’s crazy day! ATB, Scfc

[philanderer] 19/4/2018 23:38

Exactly bc, a lot of people have made a lot of money over this farce.

[blueclyde] 19/4/2018 23:36

Good finds Phil as you have pointed out they simply don't have the cash to do this. It's not happening. It would be ridiculous if they agreed to a takeover where the Shire share holders hold the majority of the shares. That isn't a takeover and simply why this will not happen. I expect a move back down to the low 30s for the time being. The whole thing was a farce insiders were able to play the share price like a fiddle.

[philanderer] 19/4/2018 23:32

Yes , I reckon the hot money will want out.



Japanese giant Takeda faces uphill battle to buy drug maker Shire after £42bn bid rejected


"..Shire told it's Japanese suitor to find more cash"

[mbmiah] 19/4/2018 23:08

This could tank tomorrow then....oh dear....the tingling greed feeling took over me afternoon

[scfc1] 19/4/2018 22:58

romeike, Shire closed down 1.1% (at $160.74) on the NASDAQ. Fell over 8% from its daily high. Scfc

[costax1654x] 19/4/2018 22:57

Anyone investing in PANR as well?I reckon I will be an easy 20% this week

[scfc1] 19/4/2018 22:56

DUBLIN, April 19, 2018 /PRNewswire/ -- In order to comply with the requirements of the UK Takeover Code, Allergan announced that it does not intend to make an offer for Shire.

[mbmiah] 19/4/2018 22:39

Allergan share price didn't really recover then lol - it's still in pursuit I reckon.

[romeike] 19/4/2018 22:28

£46.50 is a serious bid, but it's too low and too weighted as paper, with cash paid as USD. And on top of that their bid is littered with strings.

[montyhedge] 19/4/2018 22:13

Takeda no chance of serious bid.

[steeplejack] 19/4/2018 21:48

Shire has come full circle.Escaped Abbvie.Did a canny dodge in buying Baxalta but the tax benefits were overhauled by time and the debt has become oppressive.Shire remains very vulnerable and it knows as much.The market rightly suspects that it could be a bridge too far for Takeda but Shire has been put in play and the likelihood of a bid from elsewhere remains probable.

[romeike] 19/4/2018 21:18

I suspect that Allergan was "outed" and was not ready, hadn't sounded out key investors etc.

[philanderer] 19/4/2018 21:03

US close , more or less 3800p on the nose.

[karateboy] 19/4/2018 20:59

I think the other bidders may surface as soon as SHP accepts the new improved Takeda bid. I guess this weekend advisors not going home and instead hammering out an offer that are acceptable to both parties.

[ny boy] 19/4/2018 20:52

I think they are playing the usual game of cat & mouse, don’t be surprised to see them enter the fray in a few weeks once again, depends whether or not they are happy for a rival to bag the Shire prize?

Any other likely bidders?

[montyhedge] 19/4/2018 20:45

How can Allergan say looking at Shire, then two hours later say no bid.Looks like down in the morning.

[romeike] 19/4/2018 20:44

The suggestion is that Shire management want a bit more on the price, but are more concerned with improving the cash:equity ratio.

[karateboy] 19/4/2018 20:15

It looks we are left with Takeda bid For a time being. Allergan has $30b of debt and can't afford to double its debts to buy SHP. SHP must be cheep that Allergan tempted to have a go at it. Let's see what happens to Tekeda bid. SHP board has requested that SHP advisers and Takeda advisers to sit down and try to come up with another offer. I think the next offer will be accepted by SHP board, otherwise no point of requesting advisers to look into a new offer.